Trial
NCT07000344
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
UnknownTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Peking Union Medical College Hospital
Collaborators
—
Condition
Ovarian Cancer
Intervention
Cohort 1 (triple-drug group)
Why stopped
Results failed to achieve the anticipated effect.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-09